# Qualification of Biomarker — Galactomannan in studies of treatments of invasive - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-biomarker-galactomannan-in-studies-of-treatments-of-invasive/609be9e9-d86e-4995-b7df-7b9095d54037

> FDA guidance document: Qualification of Biomarker — Galactomannan in studies of treatments of invasive. Issue date: November 13, 2015. Get complete insights and analysis.

---

## Details

- Title: Qualification of Biomarker — Galactomannan in studies of treatments of invasive
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2015-11-13
- Last Changed: 2020-04-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2013-D-1630">FDA-2013-D-1630</a>

## Related Documents

- [Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data](https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hbv-resistance-data/937abe21-af65-46ce-83a8-963a0fb30d4f)
- [Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-biomarker-total-kidney-volume-in-studies-for-treatment-of-autosomal-dominant-polycystic-kidney-disease-draft-guidance-for-industry/796ecc64-f708-40c5-b86c-611463dab75b)
- [Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-biomarker-plasma-fibrinogen-in-studies-examining-exacerbations-andor-all-cause-mortality-in-patients-with-chronic-obstructive-pulmonary-disease-guidance-for-industry/01af26cc-b214-4770-8a30-fe46c0ed1bac)